NKF-FDA-EMA Workshop

The National Kidney Foundation (NKF), along with the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) concluded a scientific workshop collaboration to review the results of a major, multi-year meta-analysis examining the largest compilation of data ever collected on chronic kidney disease (CKD).

The groups gathered reviewed the data supporting the use of earlier markers of kidney disease progression as endpoints in clinical trials for early stages of CKD. These clinical trials may lead to treatments that will improve the lives of people with kidney disease. The extensive meta-analysis included data on nearly two million participants. Read the full press release.


If you would like additional information about this initiative, please contact Tom Manley.